<?xml-stylesheet type='text/xsl' href='ctgovTransform.xsl'?>
<CT.GOV_Trial requestNumber="5984">
  <stage>Registered</stage>
  <submitdate>18/05/2016</submitdate>
  <approvaldate>18/05/2016</approvaldate>
  <nctid>NCT02843321</nctid>
  <trial_identification>
    <studytitle>Combined Infusion of Cytotoxic T-Lymphocytes and Vaccination</studytitle>
    <scientifictitle>Combined Infusion of Cytotoxic T-Lymphocytes and Vaccination to Enhance Infection-Specific Immune Reconstitution Post-Allogeneic Stem Cell Transplantation</scientifictitle>
    <utrn />
    <trialacronym>CYNTAX</trialacronym>
    <secondaryid>Cyntax</secondaryid>
  </trial_identification>
  <conditions>
    <healthcondition>Complication of Transplant</healthcondition>
  </conditions>
  <interventions>
    <interventions>Other interventions - T-cell infusion, influenza vaccination

Experimental: T-cell infusion - Infusion of donor-derived T cells. Non randomised, prevention study arm


Other interventions: T-cell infusion, influenza vaccination
Donor derived infection-specific T-cells (with activity against CMV,adenovirus, EBV, VZV, Influenza, BKV and Aspergillus) and vaccination (with Fluvax)

</interventions>
    <comparator />
    <control />
    <interventioncode>Other interventions interventions</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>Safety of infection-specific T-cell infusion and vaccination - Presence of acute infusion related toxicities</outcome>
      <timepoint>1 week</timepoint>
    </primaryOutcome>
    <secondaryOutcome>
      <outcome>Change in infection specific immune reconstitution</outcome>
      <timepoint>1 week, 2 weeks, 3 weeks, 4 weeks, 3 months, 6 months, 9 months, 12 months (post T-cell infusion)</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Change in CMV, EBV and BKV load based on quantitive PCR</outcome>
      <timepoint>1 week, 2 weeks, 3 weeks, 4 weeks, 3 months, 6 months, 9 months, 12 months (post T-cell infusion)</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Use of specific anti-viral pharmacotherapy</outcome>
      <timepoint>12 months (post T-cell infusion)</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Use of systemic anti-fungal drugs including amphotericin and azoles</outcome>
      <timepoint>12 months (post T-cell infusion)</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Incidences of GVHD</outcome>
      <timepoint>12 months (post T-cell infusion)</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Number of in-hospital days following first discharge post transplant</outcome>
      <timepoint>12 months (post T-cell infusion)</timepoint>
    </secondaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>-  Patients undergoing myeloablative or non-myeloablative allogeneic transplantation from
             an HLA (A, B and DR) identical or 1-3 antigen mismatched family or unrelated donor.

          -  Transplant performed for any type of non-malignant condition or haematological
             malignancy including but not limited to acute and chronic leukaemia, myelodysplasia,
             non Hodkgins and Hodgkin lymphoma or myeloma.

          -  Recipients of peripheral blood or bone marrow stem cells.

          -  Adequate hepatic and renal function (&lt; 3 x upper limit of normal for AST (SGOT), ALT
             (SGPT), &lt; 2 x upper limit of normal for total bilirubin, serum creatinine).

          -  Estimated life expectancy of at least 6 months.

          -  Patient (or legal representative) has given informed consent</inclusivecriteria>
    <inclusiveminage />
    <inclusiveminagetype>No limit</inclusiveminagetype>
    <inclusivemaxage />
    <inclusivemaxagetype>No limit</inclusivemaxagetype>
    <inclusivegender>Both males and females</inclusivegender>
    <healthyvolunteer>Yes</healthyvolunteer>
    <exclusivecriteria>-  Use of anti-lymphocyte globulin (ALG, ATG, Campath or other broad spectrum lymphocyte
             antibody) given in the 4 weeks immediately prior to infusion or planned within 4 weeks
             after infusion.

          -  Grade II or greater graft versus host disease within 1 week prior to infusion.

          -  Prednisone or methylprednisone at a dose of &gt; 1 mg/kg (or equivalent in other steroid
             preparations) administered within 72 hours prior to cell infusion.

          -  Allergies to eggs or components of the Fluvax or Varivax vaccines.

          -  Privately insured in or outpatients</exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Interventional</studytype>
    <purpose>Treatment</purpose>
    <allocation />
    <concealment />
    <sequence />
    <masking>Blinded (masking used)</masking>
    <assignment>Single group</assignment>
    <designfeatures />
    <endpoint />
    <statisticalmethods />
    <masking1 />
    <masking2 />
    <masking3 />
    <masking4 />
    <patientregistry />
    <followup />
    <followuptype />
    <purposeobs />
    <duration />
    <selection />
    <timing />
  </trial_design>
  <recruitment>
    <phase>Phase 1</phase>
    <anticipatedstartdate />
    <actualstartdate>1/08/2012</actualstartdate>
    <anticipatedenddate />
    <actualenddate />
    <samplesize />
    <actualsamplesize>12</actualsamplesize>
    <recruitmentstatus>Active, not recruiting</recruitmentstatus>
    <anticipatedlastvisitdate>1/12/2017</anticipatedlastvisitdate>
    <actuallastvisitdate />
    <dataanalysis />
    <withdrawnreason />
    <withdrawnreasonother />
    <recruitmentcountry>Australia</recruitmentcountry>
    <recruitmentstate>NSW</recruitmentstate>
    <hospital>Westmead Hospital Department of Haematology - Westmead, Sydney</hospital>
    <postcode>2145 - Westmead, Sydney</postcode>
  </recruitment>
  <sponsorship>
    <primarysponsortype>Other</primarysponsortype>
    <primarysponsorname>University of Sydney</primarysponsorname>
    <primarysponsoraddress />
    <primarysponsorcountry />
  </sponsorship>
  <ethicsAndSummary>
    <summary>To assess the safety and biological efficacy of prophylactically administered donor-derived
      multi-infection specific cytotoxic T lymphocytes (CTLs) (targeting cytomegalovirus (CMV),
      Adenovirus (Adv), Epstein Barr virus (EBV), Varicella-Zoster virus (VZV), Influenza (Flu), BK
      virus (BKV), and Aspergillus (Asp)) combined with early immunisation with Influenza and VZV
      vaccines for the prevention of viral and fungal infection following allogeneic blood or
      marrow stem cell transplantation.</summary>
    <trialwebsite>https://clinicaltrials.gov/show/NCT02843321</trialwebsite>
    <publication />
    <ethicsreview />
    <publicnotes />
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title />
      <name>David Gottlieb, Professor</name>
      <address>Westmead Hospital</address>
      <phone />
      <fax />
      <email />
      <country />
      <type>Principal Investigator</type>
    </contact>
    <contact>
      <title />
      <name />
      <address />
      <phone />
      <fax />
      <email />
      <country />
      <type>Public Queries</type>
    </contact>
  </contacts>
</CT.GOV_Trial>